U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298538) titled 'Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer' on Nov. 25.
Brief Summary: This study reviewed real-world outcomes of patients with unresectable hepatocellular carcinoma who received lenvatinib-based treatment. The study evaluated long-term survival, treatment response, and safety using data collected from six hospitals.
Study Start Date: Jan. 01, 2019
Study Type: OBSERVATIONAL
Condition:
Unresectable Hepatocellular Carcinoma
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Disclaimer: Curated by HT Syndication....